Use of such algorithms will aid in the discovery of future A2A antagonists for the treatment of CNS disorders, such as PD and AD, or for treatment of peripheral conditions in which CNS penetration would cause side effects. This evidence concerns the gene IGKV2D-29 and Parkinson disease.